Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

(2021) Shaocong Wu et al.   Molecular Cancer

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)

(2021) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

(2021) Hiroaki Akamatsu et al.   JAMA Oncology

Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy

(2021) Lingge Cheng et al.   JOURNAL OF ETHNOPHARMACOLOGY

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

(2020) G.R. Oxnard et al.   ANNALS OF ONCOLOGY

Tumor Immunology and Tumor Evolution: Intertwined Histories

(2020) Jérôme Galon et al.   IMMUNITY

Top 10 Challenges in Cancer Immunotherapy

(2020) Priti S. Hegde et al.   IMMUNITY

Endothelial Lactate Controls Muscle Regeneration from Ischemia by Inducing M2-like Macrophage Polarization

(2020) Jing Zhang et al.   Cell Metabolism

Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer

(2020) Helena A. Yu et al.   CLINICAL CANCER RESEARCH

Beyond osimertinib: The development of 3rd-generation EGFR Tyrosine Kinase Inhibitors

(2020) Misako Nagasaka et al.   Journal of Thoracic Oncology

VEGF in Signaling and Disease: Beyond Discovery and Development

(2019) Rajendra S. Apte et al.   CELL

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

(2019) Ming Yi et al.   Molecular Cancer

The Tumor Metabolic Microenvironment: Lessons from Lactate

(2019) Juan C. García-Cañaveras et al.   CANCER RESEARCH

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

(2019) Anqi Lin et al.   Molecular Cancer

Therapeutic Targeting of the Colorectal Tumor Stroma

(2019) Wolf H. Fridman et al.   GASTROENTEROLOGY

A view on drug resistance in cancer

(2019) Neil Vasan et al.   NATURE

Identification of bioactive anti-angiogenic components targeting tumor endothelial cells in Shenmai injection using multidimensional pharmacokinetics

(2019) Chongjin Zhong et al.   Acta Pharmaceutica Sinica B

Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer

(2018) Lydia Meder et al.   CANCER RESEARCH

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Endothelial Cell Metabolism

(2018) Guy Eelen et al.   PHYSIOLOGICAL REVIEWS

Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity

(2018) Michael D. Kornberg et al.   SCIENCE

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease

(2018) Maximilian Hochmair   Targeted Oncology

Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells

(2018) Oliver A. Stone et al.   Nature Communications

Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α–mediated tumor progression

(2018) Na Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Comprehensive identification of peptides in tandem mass spectra using an efficient open search engine

(2018) Hao Chi et al.   NATURE BIOTECHNOLOGY

PRKAA1/AMPKα1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis

(2018) Qiuhua Yang et al.   Nature Communications

FGF-dependent metabolic control of vascular development

(2017) Pengchun Yu et al.   NATURE

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

HIF-1α is required for disturbed flow-induced metabolic reprogramming in human and porcine vascular endothelium

(2017) David Wu et al.   eLife

Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development

(2016) A. Yver   ANNALS OF ONCOLOGY

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment

(2016) Jin-Sung Park et al.   CANCER CELL

Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy

(2016) Anna Rita Cantelmo et al.   CANCER CELL

The Emerging Hallmarks of Cancer Metabolism

(2016) Natalya N. Pavlova et al.   Cell Metabolism

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

(2016) P. Ballard et al.   CLINICAL CANCER RESEARCH

Oxidation of an Exposed Methionine Instigates the Aggregation of Glyceraldehyde-3-phosphate Dehydrogenase

(2014) Andre L. Samson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

(2014) M. Raymond V. Finlay et al.   JOURNAL OF MEDICINAL CHEMISTRY

Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step

(2014) Alexander A Shestov et al.   eLife

Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis

(2013) Chih-Hao Chang et al.   CELL

Role of PFKFB3-Driven Glycolysis in Vessel Sprouting

(2013) Katrien De Bock et al.   CELL

TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types

(2012) Amit Chaudhary et al.   CANCER CELL

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-  Inducible Chemokines

(2012) W. Peng et al.   CANCER RESEARCH

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting

(2010) Lars Jakobsson et al.   NATURE CELL BIOLOGY

Target identification using drug affinity responsive target stability (DARTS)

(2009) B. Lomenick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE